Skip to Main Content
Table 2.

Association between MnSOD polymorphism and prostate cancer risk

CategoriesMnSOD genotype
VVVAAA
Controls, N 190 379 195 
All prostate cancer (567 cases)    
    Cases, N 132 288 147 
    RR (95% CI) 1.00 (Reference) 1.09 (0.84-1.43) 1.09 (0.80-1.49) 
By disease status*    
Nonaggressive prostate cancer (281 cases)    
    Cases, N 67 143 71 
    RR (95% CI) 1.00 (Reference) 1.06 (0.75-1.49) 1.01 (0.68-1.50) 
Aggressive prostate cancer (275 cases)    
    Cases, N 64 139 72 
    RR (95% CI) 1.00 (Reference) 1.09 (0.77-1.54) 1.10 (0.74-1.62) 
CategoriesMnSOD genotype
VVVAAA
Controls, N 190 379 195 
All prostate cancer (567 cases)    
    Cases, N 132 288 147 
    RR (95% CI) 1.00 (Reference) 1.09 (0.84-1.43) 1.09 (0.80-1.49) 
By disease status*    
Nonaggressive prostate cancer (281 cases)    
    Cases, N 67 143 71 
    RR (95% CI) 1.00 (Reference) 1.06 (0.75-1.49) 1.01 (0.68-1.50) 
Aggressive prostate cancer (275 cases)    
    Cases, N 64 139 72 
    RR (95% CI) 1.00 (Reference) 1.09 (0.77-1.54) 1.10 (0.74-1.62) 
*

Aggressive prostate cancer, stage C or D, high-grade tumor (Gleason score 7-10), or prostate cancer deaths during the follow-up; nonaggressive prostate cancer, stage A or B and low-grade (Gleason score 2-6) tumor; 11 cases with unknown disease status were excluded.

Close Modal

or Create an Account

Close Modal
Close Modal